The Cancer Institute NSW Premier’s Awards for Outstanding Cancer Research is an annual event that celebrates excellence and innovation in cancer research. Seven awards were presented on Friday, August 22, to those leading the way in their field.
Dr Glen Reid, from the Asbestos Disease Research Institute, accepted one of the awards – the Excellence in Translational Cancer Research ($20,000) – on behalf of a team from:
- Asbestos Diseases Research Institute (ADRI)
- EnGeneIC Ltd
- Royal Prince Alfred Hospital
- Strathfield Private Hospital
- Royal North Shore Hospital
- Concord Repatriation General Hospital
The multidisciplinary team of scientists, clinicians and biotech experts from six organisations investigating malignant pleural mesothelioma (MPM), used tumour samples stored in the ADRI mesothelioma biobank, one of Australia’s largest repositories of tumour samples, to identify a consistent change in how a particular family of genes work in MPM that, when corrected, stops the cancer cells growing. This research has been rapidly brought to clinical trial stage, in less than three years.
The MesomiR-1 trial is the first to focus on MPM and Non-Small Cell Lung Cancer (NSCLC), for which few treatment options exist. The trial represents a new approach to therapy for these cancers.
Read more here: http://www.cancerinstitute.org.au/news-events/latest-news/2014-nsw-outstanding-cancer-researcher-of-the-year-announced